Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

Bryan T.J. Hennessy, Kirsten M. Timms, Mark S. Carey, Alexander Gutin, Larissa A. Meyer, Darl D. Flake, Victor Abkevich, Jennifer Potter, Dmitry Pruss, Pat Glenn, Yang Li, Jie Li, Ana Maria Gonzalez-Angulo, Karen Smith McCune, Maurie Markman, Russell R. Broaddus, Jerry S. Lanchbury, Karen H. Lu, Gordon B. Mills

Research output: Contribution to journalArticlepeer-review

283 Scopus citations

Fingerprint

Dive into the research topics of 'Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences